ArticleClinical and translational science2026
Genetic Landscape of NAT2 in the Moroccan Population: Implications for Isoniazid Pharmacogenetics in Tuberculosis.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NAT2 gene encodes N-acetyltransferase 2, an enzyme critically involved in the biotransformation of numerous xenobiotics and aromatic amines, including isoniazid, a cornerstone drug in tuberculosis therapy. Genetic polymorphisms in NAT2 lead to variable acetylation rates, clinically categorized as poor, intermediate, or rapid metabolizer phenotypes influencing drug efficacy and toxicity. This study aims to characterize the NAT2 polymorphisms in 240 Moroccan individuals using pre-existing clinical exome sequencing data. A total of fourteen variants were identified in the NAT2 coding region, with the most frequent being c.341 T>C (50%), c.803G>A (48.95%), c.481C>T (48.33%), and c.282C>T (29.16%). Diplotype-based phenotype prediction showed that 148 individuals (61.67%) were poor metabolizers, 71 (29.58%) intermediate metabolizers, and 14 (5.83%) rapid metabolizers. Seven individuals could not be classified due to the presence of variants with unreported diplotype-phenotype correlations. These findings provide a comprehensive pharmacogenetic profile of NAT2 in the Moroccan population and support the implementation of diplotype-guided isoniazid dosing strategies in tuberculosis-endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.